FDA Launches PreCheck Pilot and ANDA Prioritization Program to Accelerate Domestic Manufacturing Reviews

Four overlapping incentive programs from FDA are now reshaping how plant heads and regulatory affairs teams should sequence facility buildouts, ANDA submissions, and inspection readiness for U.S.-based operations. The agency's package, published July 9, 2026, creates structured pathways that reward domestic sourcing and early regulatory engagement with measurably shorter review timelines.

The PreCheck Pilot Program is the most operationally significant for greenfield and expansion projects. Structured in two phases, it opens a Facility Readiness Phase where manufacturers receive technical and regulatory feedback before operations begin, followed by an Application Submission Phase with enhanced FDA engagement to resolve manufacturing questions and expedite inspection scheduling. On June 29, 2026, FDA named seven inaugural participants: Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. Facilities not yet in that cohort should monitor FDA's guidance on future enrollment windows.

For generic manufacturers, the ANDA Prioritization Pilot Program sets a clear qualification threshold: bioequivalence testing conducted in the United States (or covered by a waiver), finished dosage form manufactured domestically, and active pharmaceutical ingredients sourced exclusively from U.S.-based suppliers. Meeting all three criteria unlocks priority review status, accessible through FDA's existing ANDA prioritization procedures. QA and regulatory leads should audit current API supply chains now to identify any foreign-sourced inputs that would disqualify an application.

Two additional programs extend the framework. The Commissioner's National Priority Voucher (CNPV) Pilot offers accelerated, multidisciplinary review for drugs and biologics addressing public health emergencies, unmet medical needs, or domestic supply chain resilience. Unlike traditional Priority Review Vouchers, CNPVs are non-transferable and carry no secondary market value, removing the speculative dimension that has complicated PRV planning for some sponsors. Separately, Operation TrialBlazer, an HHS-FDA initiative, targets clinical development timelines through streamlined CMC requirements for early-phase studies and an expedited Phase 1 IND pilot, relevant for manufacturers with integrated development pipelines.

Across all four programs, the common thread is earlier and more structured FDA engagement, a posture consistent with ICH Q10 pharmaceutical quality system principles and the agency's longstanding Pre-Approval Inspection framework under 21 CFR Part 211. Facilities that have already invested in robust process validation documentation and CAPA infrastructure are better positioned to move quickly through the Facility Readiness Phase and ANDA qualification criteria.

The ANDA Prioritization Pilot's API sourcing requirement will serve as the first hard filter separating qualifying applicants from the broader generic pipeline as submissions accumulate.

Source: FDA via What's New: Drugs RSS Feed, July 9, 2026.